Skip to Content

Lidocaine Injection

Last Updated: November 19, 2018
Status: Current

Products Affected - Description
    • Xylocaine injection, Fresenius Kabi, 0.5%, 50 mL vial, 25 count, NDC 63323-0484-57
    • Xylocaine injection, Fresenius Kabi, 1%, 20 mL vial, 25 count, NDC 63323-0485-27
    • Xylocaine injection, Fresenius Kabi, 1%, 50 mL vial, 25 count, NDC 63323-0485-57
    • Xylocaine injection, Fresenius Kabi, 2%, 10 mL vial, 25 count, NDC 63323-0486-17
    • Xylocaine injection, Fresenius Kabi, 2%, 20 mL vial, 25 count, NDC 63323-0486-27
    • Xylocaine injection, Fresenius Kabi, 2%, 50 mL vial, 25 count, NDC 63323-0486-57
    • Xylocaine-MPF injection, Fresenius Kabi, 0.5%, 50 mL vial, 25 count, NDC 63323-0491-57
    • Xylocaine-MPF injection, Fresenius Kabi, 1%, 10 mL sterile-pack ampule, 5 count, NDC 63323-0492-97
    • Xylocaine-MPF injection, Fresenius Kabi, 1%, 2 mL vial, 25 count, NDC 63323-0492-27
    • Xylocaine-MPF injection, Fresenius Kabi, 1%, 30 mL sterile-pack vial, 5 count, NDC 63323-0492-31
    • Xylocaine-MPF injection, Fresenius Kabi, 1%, 30 mL vial, 25 count, NDC 63323-0492-37
    • Xylocaine-MPF injection, Fresenius Kabi, 1%, 5 mL vial, 25 count, NDC 63323-0492-57
    • Xylocaine-MPF injection, Fresenius Kabi, 1.5%, 20 mL ampule, 5 count, NDC 63323-0493-91
    • Xylocaine-MPF injection, Fresenius Kabi, 2%, 10 mL ampule, 5 count, NDC 63323-0496-97
    • Xylocaine-MPF injection, Fresenius Kabi, 2%, 2 mL vial, 25 count, NDC 63323-0495-27
    • Lidocaine Hydrochloride injection, AuroMedics, 1%, 2 mL ampule, 10 count, NDC 55150-0158-72
    • Lidocaine Hydrochloride injection, AuroMedics, 1%, 2 mL vial, 10 count, NDC 55150-0161-02
    • Lidocaine Hydrochloride injection, AuroMedics, 1%, 30 mL vial, 1 count, NDC 55150-0163-30
    • Lidocaine Hydrochloride injection, AuroMedics, 1%, 5 mL ampule, 10 count, NDC 55150-0159-74
    • Lidocaine Hydrochloride injection, AuroMedics, 1%, 5 mL vial, 10 count, NDC 55150-0162-05
    • Lidocaine Hydrochloride injection, AuroMedics, 2%, 2 mL ampule, 10 count, NDC 55150-0160-72
    • Lidocaine Hydrochloride injection, AuroMedics, 2%, 2 mL vial, 10 count, NDC 55150-0164-02
    • Lidocaine Hydrochloride injection, AuroMedics, 2%, 5 mL vial, 10 count, NDC 55150-0165-05
    • Lidocaine Hydrochloride injection, Fresenius Kabi, 1%, 10 mL vial, 25 count, NDC 63323-0201-10
    • Lidocaine Hydrochloride injection, Fresenius Kabi, 1%, 2 mL vial, 25 count, NDC 63323-0201-02
    • Lidocaine Hydrochloride injection, Fresenius Kabi, 2%, 2 mL vial, 25 count, NDC 63323-0202-02
    • Lidocaine Hydrochloride injection, Fresenius Kabi, 2%, 5 mL Tear-top preservative-free vial, 25 count, NDC 63323-0208-05
    • Lidocaine Hydrochloride injection, Hikma, 1%, 50 mL vial, 10 count, NDC 00143-9577-10
    • Lidocaine Hydrochloride injection, Hikma, 2%, 5 mL preservative-free vial, 25 count, NDC 00143-9594-25
    • Lidocaine Hydrochloride injection, Hikma, 2%, 50 mL vial, 10 count, NDC 00143-9575-10
    • Lidocaine Hydrochloride injection, Pfizer, 0.5%, 50 mL SD Tear Top preservative-free vial, 25 count, NDC 00409-4278-01
    • Lidocaine Hydrochloride injection, Pfizer, 0.5%, 50 mL SD Flip Top vial, 25 count, NDC 00409-4275-01
    • Lidocaine Hydrochloride injection, Pfizer, 1%, 2 mL preservative-free glass ampule, 50 count, NDC 00409-4713-32
    • Lidocaine Hydrochloride injection, Pfizer, 1%, 20 mL vial, 25 count, NDC 00409-4276-01
    • Lidocaine Hydrochloride injection, Pfizer, 1%, 30 mL preservative-free vial, 25 count, NDC 00409-4279-02
    • Lidocaine Hydrochloride injection, Pfizer, 1%, 5 mL emergency Ansyr syringe, 10 count, NDC 00409-9137-05
    • Lidocaine Hydrochloride injection, Pfizer, 1%, 5 mL LifeShield syringe, 10 count, NDC 00409-4904-34
    • Lidocaine Hydrochloride injection, Pfizer, 1%, 5 mL preservative-free glass ampule, 50 count, NDC 00409-4713-02
    • Lidocaine Hydrochloride injection, Pfizer, 1%, 50 mL vial, 25 count, NDC 00409-4276-02
    • Lidocaine Hydrochloride injection, Pfizer, 1.5%, 20 mL preservative-free ampule, 25 count, NDC 00409-4776-01
    • Lidocaine Hydrochloride injection, Pfizer, 2%, 10 mL preservative-free glass ampule, 25 count, NDC 00409-4282-02
    • Lidocaine Hydrochloride injection, Pfizer, 2%, 2 mL preservative-free glass ampule, 25 count, NDC 00409-4282-01
    • Lidocaine Hydrochloride injection, Pfizer, 2%, 20 mL vial, 25 count, NDC 00409-4277-01
    • Lidocaine Hydrochloride injection, Pfizer, 2%, 5 mL emergency Ansyr syringe, 10 count, NDC 00409-1323-05
    • Lidocaine Hydrochloride injection, Pfizer, 2%, 5 mL LifeShield syringe, 10 count, NDC 00409-4903-34
    • Lidocaine Hydrochloride injection, Pfizer, 2%, 5 mL preservative-free vial, 10 count, NDC 00409-2066-05
    • Lidocaine Hydrochloride injection, Pfizer, 2%, 50 mL vial, 25 count, NDC 00409-4277-02
    • Lidocaine Hydrochloride injection, Pfizer, 4%, 5 mL preservative-free glass ampule, 25 count, NDC 00409-4283-01
Reason for the Shortage
    • Amphastar had lidocaine 2% emergency syringes on shortage due to increase demand for the product.
    • AuroMedics introduced lidocaine injection in February 2014.
    • Fresenius Kabi had generic lidocaine presentations on shortage due to a supply interruption of raw ingredients.
    • Pfizer has lidocaine presentations on shortage due to manufacturing delays.
Available Products
    • Xylocaine-MPF injection, Fresenius Kabi, 1.5%, 10 mL ampule, 5 count, NDC 63323-0493-97
    • Xylocaine-MPF injection, Fresenius Kabi, 2%, 5 mL vial, 25 count, NDC 63323-0495-07
    • Lidocaine Hydrochloride injection, Amphastar, 2%, 5 mL Luer-Jet Emergency syringe, 10 count, NDC 76329-3390-01
    • Lidocaine Hydrochloride injection, Hikma, 1%, 5 mL preservative-free vial, 25 count, NDC 00143-9595-25

Estimated Resupply Dates

    • AuroMedics has 1% lidocaine 2 mL and 5 mL ampules and 2 mL, 5 mL, and 30 mL vials on intermittent back order and the company is releasing product as it becomes available. AuroMedics has 2% lidocaine 2 mL ampules and 2 mL and 5 mL vials on intermittent back order and the company is releasing product as it becomes available.
    • Fresenius Kabi has 0.5% Xylocaine 50 mL vials on back order and the company cannot estimate a release date. The 0.5% Xylocaine 50 mL MPF vials are on back order and the company estimates a release date of early-December 2018. The 1% lidocaine 2 mL and 10 mL vials are on back order and the company estimates a release date of mid- to late-November 2018 for the 2 mL vials and early-January 2019 for the 10 mL vials. The 1% Xylocaine 20 mL and 50 mL vials are on back order and the company estimates a release date of mid- to late-November 2018 for the 20 mL vials and early-December 2018 for the 50 mL vials. The 1% Xylocaine-MPF 2 mL, 5 mL, and 30 mL vials are on back order and the company estimates a release date of mid- to late-November 2018 for the 2 mL vials, early-December 2018 for the 5 mL vials, and early-January 2019 for the 30 mL vials. The 1% Xylocaine-MPF 10 mL ampule sterile packs are on back order and the company estimates a release date of mid-January 2019. The 1% Xylocaine-MPF 30 mL vial sterile packs are on back order and the company cannot estimate a release date. The 1.5% Xylocaine-MPF 20 mL ampules are on back order and the company cannot estimate a release date. The 2% Xylocaine 10 mL, 20 mL, and 50 mL vials are on back order and the company estimates a release date of early-December 2018 for the 10 mL vials and mid- to late-November 2018 for the 20 mL and 50 mL vials. The 2% Xylocaine-MPF 2 mL vials are on back order and the company estimates a release date of early-December 2018. The 2% Xylocaine-MPF 10 mL ampules are on back order and the company estimates a release date of mid-January 2019. The 2% lidocaine 2 mL and 5 mL vials are on back order and the company estimates a release date of mid-January 2019 for the 2 mL vials and early-December 2018 for the 5 mL vials. Check wholesalers for inventory.
    • Pfizer has 0.5% lidocaine 50 mL tear top vials on back order and the company estimates a release date of December 2018. The 0.5% lidocaine flip top vials are on back order and the company estimates a release date of 1st quarter 2019. The 1% lidocaine 2 mL preservative-free ampules on back order and the company estimates a release date of November 2018. The 1% lidocaine 5 mL preservative-free ampules are on back order and the company estimates a release date of 1st quarter 2020. The 1% lidocaine 20 mL vials and 30 mL preservative-free vials are on back order and the company estimates a release date of December 2018. The 1% lidocaine 50 mL vials are on back order and the company estimates a release date of November 2018. The 1% lidocaine 5 mL Lifeshield syringes are on back order and the company estimates a release date of December 2018. The 1% lidocaine 5 mL Ansyr syringes are on back order and the company estimates a release date of December 2018. The 1.5% lidocaine 20 mL preservative-free ampules are on back order and the company estimates a release date of 4th quarter 2019. The 2% lidocaine 2 mL preservative-free ampules are on back order and the company estimates a release date of January 2019. The 2% lidocaine 10 mL ampules are on back order and the company cannot estimate a release date. The 2% lidocaine 5 mL vials are on back order and the company estimates a release date of 4th quarter 2019. The 2% lidocaine 20 mL and 50 mL vials are on back order and the company estimates a release date of January 2019 for the 20 mL vials and December 2018 for the 50 mL vials. The 2% lidocaine 5 mL Lifeshield syringes are on back order and the company estimates a release date of 1st quarter 2019. The 2% lidocaine 5 mL Ansyr syringes are on back order and the company estimates a release date of January 2019. The 4% lidocaine 5 mL ampules are on back order and the company estimates a release date of December 2018.
    • Hikma has 1% lidocaine 50 mL vials on back order and the company estimates a release date of mid- to late-November 2018. The 2% lidocaine 5 mL and 50 mL vials are on back order and the company estimates a release date of mid- to late-November 2018.

Alternative Agents & Management

    • Bupivacaine and lidocaine are amide-type local anesthetics commonly used in clinical practice. The following table compares their pharmacodynamic and pharmacokinetic properties. Key differences between the products are onset of action, duration of action, and dose. In general, bupivacaine is a longer-acting local anesthetic, while lidocaine has a more rapid onset, but shorter duration of action.[1-2]
    Table 1. Table. Comparison of Bupivacaine and lidocaine for Local Anesthesia1-6
    Property Bupivacaine Lidocaine
    *Duration of effect is prolonged by use of local anesthetics in combination with epinephrine, although magnitude of effect is not well-defined for all routes.
    Onset of action Infiltration: 2-10 min
    Epidural: 4-7 min
    Spinal: 1-15 min
    Not well-defined for anesthetic use as a single agent.
    In general local analgesia 1 to 3 min
    Spinal and Epidural rapid onset
    Duration of action:
    As a single agent
    Infiltration: 2-8 h
    Nerve block, minor: 3-6 h
    Epidural: 3-9 h
    Spinal: 1.5-3.5 h
    Infiltration: 0.5-2 h
    Nerve block, minor: 1-2 h
    Epidural: 100 min
    Spinal: 0.5-2 h
    Duration of action: Combined with epinephrine* Infiltration: 3-4 h
    Nerve block, minor: 4-7 h
    Infiltration: 2 h
    Nerve block, minor: 2-3 h
    Maximum dose Single injections up to 175 mg without epinephrine or 225 mg with epinephrine; may repeat up to once every 3 hours.
    Maximum dosage: 400 mg/24 hours.
    Maximum: 4.5 mg/kg/dose not to exceed 300 mg without epinephrine or 7mg/kg/dose not to exceed 500 mg with epinephrine; do not repeat within 2 hours.
    Maximum dose for spinal anesthesia is 100 mg.
    Protein Binding 82%-96% 60%-80%
    Volume of distribution ~2.5 L/kg 1.5 + 0.6 L/kg
    Half-life, terminal Adults: 1.5-5 h
    Neonates: 8.1 h
    Adults: 1.5-2 h
    Premature infants: 3.2 h
    Metabolism Undergoes N-dealkylation in the liver. Extensive hepatic metabolism (90%) with active metabolites.
    Elimination Excreted in urine as metabolites and 5% as unchanged drug. Excreted in urine as metabolites (90%) and unchanged drug (< 10 %).

References

    1. Berde CB, Strichartz GR. Local anesthetics. In: Miller RD, ed. Miller's Anesthesia. 8th ed. Philadelphia, PA: Elsevier Saunders;2015:1028-1054.e4.
    2. Drasner K. Local anesthetics. In: Miller RD, Pardo MC, ed. Basics of Anesthesia. 6th ed. Philadelphia, PA: Elsevier Saunders;2011:130-142.
    3. Drugdex system. Micromedex 2.0 [database online]. http://www.micromedexsolutions.com. Updated March 13, 2018. Greenwood Village, CO: Truven Health Analytics; Accessed March 13, 2018.
    4. Lexi-Drugs Online. Hudson, OH: Lexi-Comp, Inc; 2018.
    5. Lidocaine hydrochloride and epinephrine injection, solution [package insert]. Lake Forest, IL: Hospira Inc; 2017.
    6. McEvoy GK, Snow EK, Kester L, Litvak K, Miller J, Welsh OH, eds. AHFS DI (Lexi-Comp Online). Bethesda, MD: American Society of Health-System Pharmacists; 2018.

Updated

Updated November 19, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. Created June 23, 2015 by Jane Chandramouli, PharmD, Drug Information Specialist. Copyright 2018, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide